High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma (PCNSL) in First Complete Remission (CR1)

Slides:

Advertisements

Similar presentations

The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk.

Advertisements

How to Treat MDS without Stem Cell Transplantation

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin’s Lymphoma (HL) in the ABVD Therapeutic Era Sarah F. Keller,

Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant Maria Gil-Cupello, BA, Gunjan.

Outcome of Patients with Multiple Myeloma by Ethnicity in the Setting of Autologous Stem Cell Transplant Koji Sasaki, MD, Qaiser Bashir, MD, Nina Shah,

Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide (TBC) Conditioning in Patients with CNS Involvement by Non-Hodgkin.

Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma Taewoong Choi, Murali K. Kodali, Wen-Kai Weng

Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.

Primary CNS Lymphoma—Radiation-Free Salvage Therapy by Second Autologous Stem Cell Transplantation Benjamin Kasenda, M.D., Elisabeth Schorb, M.D., Kristina.

Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years Areej El-Jawahri, Shuli Li, Joseph.

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

A 15-Year Analysis of Early and Late Autologous Hematopoietic Stem Cell Transplant in Relapsed, Aggressive, Transformed, and Nontransformed Follicular.

Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront.

Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis Danielle H. Oh, Haocheng.

Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1 Andrew M. Brunner,

Low Incidence of Chronic GVHD after HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post Transplantation Cyclophosphamide in Older.

Sabina Kersting, Leo F. Verdonck

Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation

Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell.

Study Design of an Expanded Access Protocol of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients Years of Age with Secondary Acute.

Sonidegib (LDE-225), a Sonic Hedgehog Pathway Inhibitor, for the Treatment of Steroid- Refractory Chronic Graft-Versus-Host Disease Zachariah DeFilipp,

The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.

Analysis of the Prognostic Effect of Peripheral Blood Lymphocyte and Monocyte Count after Autologous Hematopoietic Stem Cell Transplant in Refractory/Relapsed.

Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigen–Mismatched Stem Cell Microtransplantation Improved Outcomes.

Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation.

High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Previously Treated Germ Cell Tumors: A Single-Center Experience Zachariah DeFilipp,

Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant Maria Gil-Cupello, BA, Gunjan.

High Rate of Long Term Complete Remission for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapse after Allogeneic Stem Cell Transplantation.

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Early Toxicities Associated with Radiation Based Conditioning for Relapsed/Refractory Hodgkin Lymphoma Patients Undergoing High Dose Therapy and Autologous.

Biology of Blood and Marrow Transplantation

Trial in Progress: Gravitas-301, a Randomized, Double-Blind Phase 3 Study of Itacitinib or Placebo with Corticosteroids (CS) for the First-Line Treatment.

Autologous Stem Cell Transplantation (ASCT) Is Effective Therapy for Older Patients with Non-Hodgkin's Lymphoma (NHL) Deepa Jagadeesh, MD, MPH, Lisa.

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute.

Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma

Autologous Stem Cell Transplant in Patients with Primary Central Nervous System Lymphoma: A Multicenter Analysis From the Sarah Cannon Blood Cancer Network

Long-Term Outcomes of Critically Ill Adult Allogeneic Hematopoietic Stem Cell Recipients Prakash Vishnu, Udit Roy, Pramod Guru, Colleen Thomas, Candido.

Eltrombopag Treatment for Primary and Secondary Thrombocytopenia Post Allogeneic and Autologous Stem Cell Transplantation is Effective and Safe Shahram.

Outcomes of Patients 65 Years and Older with Non-Hodgkin Lymphoma Receiving Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.

Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation

Hemophagocytic Lymphohistiocytosis (HLH) after Hematopoietic Stem Cell Transplant (HSCT) or an Impostor: A Word of Caution! Anant Vatsayan, MD, Linda.

Kamal Kant Singh Abbi, Junting Zheng, Sean M

Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma Christopher Parrish, Amin Rahemtulla, Jim.

Efficacy of Thiotepa-Busulfan-Cyclophosphamide (TBC) Conditioning and Autologous Transplantation As Consolidation for Systemic Non-Hodgkin Lymphoma with.

Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation Willis H. Navarro, Fausto R.

Challenges of Haematopoietic Stem Cell Transplantation in Primary Immunodeficiency Disorders in a Developing Country Anu Korula, Eunice Sindhuvi, Anup.

Results of 10-Year Single Center Experience with Pharmacokinetics Directed Intravenous Busulfan, Cyclophosphamide and Etoposide Preparative Regimen in.

Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.

Single Center Experience with High Dose Melphalan and Two Day Washout in Patients with Multiple Myeloma on Hemodialysis Undergoing Autologous Stem Cell.

Allogeneic Stem Cell Transplantation for Aplastic Anemia

Incidence of Adrenal Insufficiency in Patients with Multiple Myeloma during High Dose Chemotherapy and Autologous Stem Cell Transplant Ahmad Hatem Mattour,

Toxicities and Outcomes for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT)

Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival Victor H. Jimenez-Zepeda,

What is quality in a transplant program?

Management of Cytokine Release Syndrome (CRS) in Patients Undergoing Chimeric Antigen Receptor Modified (CAR) T-Cell Therapy Following Autologous Stem.

Influence of Body Weight on Melphalan Dosing in Autologous Stem Cell Transplantation Kendall Shultes, Christopher Arp, Keith Stockerl-Goldstein, Kathryn.

Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.

Early Fluctuations in Busulfan Levels When Using Pharmacokinetically Guided Dosing Does Not Affect Transplantation Outcomes with Busulfan-Based Conditioning.

Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic.

Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.

Mammen Chandy Biology of Blood and Marrow Transplantation

Paclitaxel-Based High-Dose Chemotherapy with Autologous Stem Cell Rescue for Relapsed Germ Cell Cancer Kim A. Margolin, James H. Doroshow, Paul Frankel,

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Pre-Transplant Comorbidity As an Outcome Predictor in Hematopoietic Cell Transplantation for Severe Aplastic Anemia SungNam Lim, Je-Hwan Lee, MD, PhD,

Megadose CD34+ Cell Grafts Improve Recovery of T Cell Engraftment but not B Cell Immunity in Patients with Severe Combined Immunodeficiency Disease Undergoing.

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Presentation transcript:

High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma (PCNSL) in First Complete Remission (CR1) Zachariah DeFilipp, Shuli Li, Areej R. El-Jawahri, Philippe Armand, Lakshmi Nayak, Tracy Batchelor, Yi-Bin Chen Biology of Blood and Marrow Transplantation Volume 23, Issue 3, Pages S82-S83 (March 2017) DOI: 10.1016/j.bbmt.2016.12.039 Copyright © 2016 Terms and Conditions

Figure 1 Kaplan-Meier estimates for progression-free and overall survival for patients with primary CNS lymphoma receiving ASCT in CR1 following a thiotepa/busulfan/cyclophosphomide-based conditioning regimen. Biology of Blood and Marrow Transplantation 2017 23, S82-S83DOI: (10.1016/j.bbmt.2016.12.039) Copyright © 2016 Terms and Conditions